LEWOS BIOTECHNOLOGYNEUROSCIENCE · PRECLINICAL CROExplore · Discover · Advance
Contact us

Core services

From target validation to candidate selection, we design the preclinical work that helps your team move forward with confidence.

Bring us a target, candidate or delivery question. We turn it into a focused study plan, with the models, dosing and evidence needed to make the next decision.

  • 200+Completed projects
  • 8Integrated platforms
  • 7Neuroscience PhDs
  • 80+High-impact papers
Explore models & evidence
01CNS EFFICACY

CNS disease models & efficacy

Neurodegeneration, neurodevelopment, psychiatric disease, stroke, traumatic brain injury, epilepsy and related CNS indications.

Best for

For candidate efficacy validation, dose or route comparison and mechanism studies.

Research questions
  • Does the model match the target and disease stage?
  • Can behavioral change be supported by tissue or molecular evidence?
  • How should dose, route and intervention window be compared?
Scope
  • Neurodegeneration: AD, PD, ALS
  • Neurodevelopment: ASD, Rett
  • Psychiatric: depression, anxiety
  • Neural injury: stroke, TBI
  • Other CNS disease: epilepsy and more
View service details
02NEUROPATHIC PAIN

Neuropathic pain efficacy

CCI, SNL and SNI models combined with mechanical, thermal and cold pain, histology and molecular endpoints.

Best for

For nerve-injury pain candidate screening, route comparison and pain-mechanism validation.

Research questions
  • Which pain dimensions respond to the candidate?
  • Does motor change confound sensory behavior?
  • Do behavior, neural, inflammatory and target readouts agree?
Scope
  • CCI chronic constriction injury
  • SNL spinal nerve ligation
  • SNI spared nerve injury
  • DRG and spinal-cord assays
View service details
03BBB DELIVERY

hTFR macromolecule brain delivery

Delivery evaluation for anti-human TfR1 antibodies, bispecifics, AOCs, ADCs and other protein therapeutics.

Best for

For comparing TfR1-targeted macromolecule delivery and, where needed, linking it to disease-model efficacy.

Research questions
  • How is the candidate distributed across brain regions after peripheral dosing?
  • How do dosing routes change target engagement?
  • Can delivery performance connect to efficacy in an indication-specific model?
Scope
  • hTFR humanized mouse
  • IV / SC peripheral dosing
  • 8+ brain regions and peripheral tissues
  • Composite models such as hTFR × 5xFAD
View service details
04NUCLEIC ACID

Nucleic acid delivery & efficacy

Compare siRNA, ASO, mRNA and LNP candidates across routes, tissue distribution and expression or knockdown.

Best for

For candidate-sequence screening, delivery-strategy comparison and target-tissue effect validation.

Research questions
  • Which candidate produces the clearest target-tissue effect?
  • How do route changes alter distribution and target engagement?
  • Do delivery, expression and knockdown results agree?
Scope
  • Liver, muscle and peripheral tissues
  • Brain, spinal cord and DRG
  • Retina and cochlea
  • SC / IV / IT / ICV and other routes
View service details

HOW PROJECTS COMBINE

How services connect

Combine services around the research question instead of forcing every project through the same end-to-end path.

Disease efficacy to mechanism

  1. Model & dosing
  2. Behavioral endpoints
  3. Pathology, molecular & electrophysiology

Use tissue, molecular or electrophysiology endpoints to test whether behavioral change has mechanistic support.

Delivery to disease efficacy

  1. TfR1-targeted delivery
  2. Brain distribution & engagement
  3. Indication-specific model

Confirm distribution and target engagement in hTFR mice, then continue efficacy work in an indication-specific model.

Nucleic-acid screening to tissue effect

  1. Candidate & route
  2. Multi-tissue collection
  3. Expression or knockdown

Compare candidates, carriers and routes under consistent conditions to select the next study direction.

These are optional combinations. Most projects use only part of the pathway, based on the candidate, development stage and existing data.

Technical contact

Tell us your candidate type, disease area, development stage and current question. We will help identify which service to use first.

+86 133 7528 3993 yijiusier@lewos.cn